Malignant pleural mesothelioma(MM), a rare tumor characterized by high local invasiveness and low metastatic efficiency, is poorly responsive to current therapeutic approaches. The aim of the present study was to evaluate the cytotoxic efficacy of the hybrid polar compound hexamethylene bisacetamide(HMBA), either as a single agent or in combination with the anthracycline doxorubicin (DOX), against MM cells.
Palumbo, C., ALBONICI BOVE, L., Bei, R., Bocci, C., Scarpa, S., DI NARDO, P., et al. (2004). HMBA induces cell death and potentiates doxorubicin toxicity in malignant mesothelioma cells, 54(5), 398-406 [10.1007/s00280-004-0838-6].
HMBA induces cell death and potentiates doxorubicin toxicity in malignant mesothelioma cells
PALUMBO, CAMILLA;ALBONICI BOVE, LOREDANA;BEI, ROBERTO;DI NARDO, PAOLO;MODESTI, ANDREA
2004-11-01
Abstract
Malignant pleural mesothelioma(MM), a rare tumor characterized by high local invasiveness and low metastatic efficiency, is poorly responsive to current therapeutic approaches. The aim of the present study was to evaluate the cytotoxic efficacy of the hybrid polar compound hexamethylene bisacetamide(HMBA), either as a single agent or in combination with the anthracycline doxorubicin (DOX), against MM cells.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.